Invivyd (NASDAQ:IVVD) Price Target Cut to $3.55 by Analysts at Morgan Stanley

Invivyd (NASDAQ:IVVD) had its price target reduced by Morgan Stanley from $9.50 to $3.55 in a report published on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities analysts have also issued reports on the stock. HC Wainwright dropped their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th.

Invivyd Stock Performance

Shares of NASDAQ:IVVD opened at $0.77 on Wednesday. The firm has a market cap of $91.88 million, a PE ratio of -0.39 and a beta of 0.65. The firm’s fifty day moving average is $0.98 and its 200-day moving average is $1.25. Invivyd has a 52 week low of $0.72 and a 52 week high of $5.20.

Institutional Investors Weigh In On Invivyd

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in Invivyd in the 1st quarter worth about $56,000. XTX Topco Ltd grew its position in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after acquiring an additional 15,376 shares during the period. Proficio Capital Partners LLC bought a new position in shares of Invivyd during the 3rd quarter valued at approximately $27,000. Tidal Investments LLC bought a new position in shares of Invivyd during the 1st quarter valued at approximately $126,000. Finally, Marshall Wace LLP lifted its stake in shares of Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after buying an additional 31,992 shares in the last quarter. 70.36% of the stock is owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.